Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195010 | 0.88 | HSD17B10 (0.68) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL10195728 | 0.88 | HSD17B10 (0.68) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL10195730 | 0.88 | HSD17B10 (0.68) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL9367355 | 0.87 | HSD17B10 (0.67) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL11919266 | 0.87 | DRD2 (0.67) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL4341169 | 0.87 | MCHR1 (0.69) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL11916163 | 0.86 | HSD17B10 (0.65) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL15317635 | 0.86 | HSD17B10 (0.65) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL15317637 | 0.86 | HSD17B10 (0.65) | HSD17B10ABCG2MCHR2MCHR1DRD2 | |
| SCHEMBL4572920 | 0.85 | DRD2 (0.60) | HSD17B10ABCG2MCHR2MCHR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101981036-B | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2013-09-04 | — | — | CN | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | HSD17B10 3045/4885ABCG2 771/4885MCHR2 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.